二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 24839.28万股，累计占流通股比： 44.61%，较上期变化： -891.08万股。 | 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 太极集团（600129）有限公司 | 15381.24 | 27.62 | 不变 | | 重庆市涪陵页岩气产业投资发展有限公司 | 4409.53 | 7.92 | 不变 | | 重庆市涪陵区希兰生物科技有限公司 | 1189.53 | 2.14 | 不变 | | 富国研究精选灵活配置混合A | 588.54 | 1.06 | 新进 | | 重庆市涪陵实业发展集团有限公司 | 585.68 | 1.05 | 不变 | | 香港中央结算有限公司 | 561.36 | 1.01 | -531.47 | | 南方中证500ETF | 556.67 | 1.00 | -82.13 | | 富国天惠成长混合(LOF) | 540.77 | 0.97 | 新进 | | 中国人寿（601628）保险股份有限公司-传 ...

Core Viewpoint - Taiji Group's subsidiaries are required to pay approximately 100 million yuan in back taxes and penalties, significantly impacting the company's projected net profit for 2024, which is expected to drop to 26.65 million yuan, a decrease of about 96.76% compared to 2023 [1][2] Group 1: Tax Payment and Financial Impact - The tax payment involves two subsidiaries: Southwest Pharmaceutical Co., Ltd. and Chongqing Chinese Medicinal Materials Co., Ltd., with Southwest Pharmaceutical responsible for approximately 80 million yuan and Chongqing Chinese Medicinal Materials for about 20 million yuan [2] - The expected net profit for 2024 was revised down from 156.4 million yuan to 26.65 million yuan due to the tax payment, indicating a substantial decline in profitability [2][4] - If non-recurring gains and losses are excluded, the net profit is projected to be around 38.54 million yuan, reflecting a year-on-year decline of 95.02% [2] Group 2: Regulatory and Compliance Issues - The tax issue follows a recent penalty related to quality control problems in the production of a specific anesthetic drug, which raises concerns about the company's compliance and operational integrity [1][5] - The regulatory scrutiny may lead to a downgrade in credit ratings for Southwest Pharmaceutical, potentially affecting its eligibility for national drug procurement in the next three years [3][5] - The company emphasizes that the tax payment does not involve administrative penalties and plans to enhance supervision and training regarding tax compliance [4][9] Group 3: Strategic Goals and Market Position - Taiji Group aims to achieve a revenue target of 50 billion yuan by 2025, but recent events have raised doubts about its ability to meet this goal, given the significant drop in projected profits and ongoing compliance issues [8][9] - The company has experienced a steady increase in revenue from 112.08 billion yuan in 2020 to 156.23 billion yuan in 2023, but the gap to the 50 billion yuan target remains considerable [8] - Balancing rapid expansion with compliance in a tightening regulatory environment poses a significant challenge for the company's management [9]

Core Viewpoint - Taiji Group announced a significant downward adjustment in its 2024 profit forecast, with a projected net profit decline of 96.76% due to tax payments and decreased sales in key product categories [1][2]. Group 1: Financial Performance - The company initially forecasted a net profit of approximately 156 million yuan for 2024, representing a year-on-year decline of about 80.98% [1]. - The revised forecast estimates a net profit of around 26.65 million yuan, marking the lowest level in nearly a decade, excluding losses in 2014, 2019, and 2021 [1]. - Revenue for 2024 is expected to decrease by approximately 32.13 billion yuan, with a decline rate of 20.56%, particularly impacted by a 42.5% drop in fourth-quarter revenue [1]. Group 2: Tax Payments - Two subsidiaries of Taiji Group, Southwest Pharmaceutical Co., Ltd. and Chongqing Chinese Medicinal Materials Co., Ltd., are required to pay a total of about 100 million yuan in taxes and penalties [2]. - Southwest Pharmaceutical is responsible for 80 million yuan in income tax, while Chongqing Chinese Medicinal Materials must pay 20 million yuan in value-added tax and penalties [2]. - The tax payments will be recorded in the 2024 fiscal year and do not involve any administrative penalties [2]. Group 3: Market Performance - On March 27, Taiji Group's stock closed at 20.88 yuan per share, reflecting a decline of 1.09% [3].

济民健康一副总裁涉嫌犯罪；太极集团两子公司补 缴税款及滞纳金1亿元｜医药早参 每经记者 陈星 每经编辑 董兴生 ｜ 2025年3月27日 星期四 ｜ NO.1 济民健康副总裁何清红涉嫌犯罪 济民健康公告，公司副总裁何清红及其团队成员于2023年3月私刻了公司及其子公司（聚民生物科技有 限公司、浙江济民堂医药贸易有限公司）的印章，并在销售过程中，冒用公司名义用假章与经销商签署 《补充协议》，约定若经销商在一定期限内（如3个月、6个月）没有实现产品销售，在不影响二次销售 的情况下，有权退回公司，公司需给予经销商所退回产品采购金额10%的资金占用补偿。 点评：何清红于2022年2月加入济民健康，任副总裁职务，主要负责预充式导管冲洗器及安全注射器国 内市场的营销工作。2023年和2024年，何清红团队合计实现销售额约11719.90万元。济民健康可能因该 事件存在被经销商起诉、退货退款并支付资金占用补偿的风险。 NO.2 太极集团下调2024年业绩预告 因控股子公司和全资子公司根据当地税务检查和企业自查情况，两子公司需补缴税款和滞纳金共计约1 亿元。上述补缴税款和滞纳金计入太极集团2024年当期损益，公司因此下调20 ...

Group 1 - The company has corrected its 2024 annual performance forecast, now expecting a net profit attributable to shareholders of approximately 26.65 million yuan, a decrease of about 79.55 million yuan compared to the previous year, representing a year-on-year decline of approximately 96.76% [1][2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is now estimated to be around 38.54 million yuan, down approximately 73.59 million yuan from the previous year, reflecting a year-on-year decline of about 95.02% [2] - The previous forecast indicated a net profit of approximately 156.40 million yuan, which has been significantly revised downwards due to tax liabilities [1][2] Group 2 - The company reported a total profit of 1,026.60 million yuan and a net profit attributable to shareholders of 822.12 million yuan for the previous year [2] - The earnings per share for the previous year was reported at 1.48 yuan [2] - The main reason for the performance forecast correction is the need to pay back taxes and penalties totaling approximately 100 million yuan, with specific amounts for different subsidiaries [2][3]

Core Viewpoint - The company announced that its subsidiaries, Southwest Pharmaceutical Co., Ltd. and Chongqing Chinese Herbal Medicine Co., Ltd., are required to pay a total of approximately 100 million yuan in back taxes and late fees due to tax inspections and self-assessments [1] Group 1: Tax Payment Details - Southwest Pharmaceutical is required to pay approximately 80 million yuan in income tax [1] - Chongqing Chinese Herbal Medicine needs to pay about 20 million yuan in value-added tax and late fees [1] - The total amount due will be recorded in the company's 2024 financial results [1] Group 2: Financial Impact - The payment of back taxes and late fees is expected to reduce the company's net profit attributable to shareholders by 100 million yuan in 2024 [2] - This tax payment does not involve any administrative penalties and will not require adjustments to prior financial statements [2] Group 3: Management Response - The company's management is taking the matter seriously and plans to enhance supervision and management of its subsidiaries [2] - There will be an emphasis on training and awareness regarding tax responsibilities to protect the interests of the company and its shareholders [2]

证券代码：600129 证券简称：太极集团 公告编号：2025-018 重庆太极实业（集团）股份有限公司 2024 年年度业绩预告更正的公告 预计 2024 年年度归属于上市公司股东的扣除非经常性损益的净 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2024 年 1 月 1 日至 2024 年 12 月 31 日。 （二）前次业绩预告情况 重庆太极实业（集团）股份有限公司（以下简称：公司）于 2025 年 1 月 24 日披露了公司《2024 年年度业绩预减公告》（公告编号： 2025-005）。前次业绩预告具体内容如下： 经财务部门初步测算，预计 2024 年年度实现归属于上市公司股 东的净利润约为 15,640 万元，与上年同期相比，下降约 66,572.49 万元，同比降幅约 80.98%。 预计 2024 年年度归属于上市公司股东的扣除非经常性损益的净 利润约为 13,421 万元，与上年同期相比，下降约 64,023.84 万元， 同比降幅约 82.67%。 （三）更正 ...

Financial Performance - The company expects a net profit attributable to shareholders of approximately 26.65 million yuan for 2024, a decrease of about 79.55 million yuan, representing a decline of approximately 96.76% year-on-year [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be around 38.54 million yuan, down approximately 73.59 million yuan, with a year-on-year decline of about 95.02% [3]. - In the previous year (2023), the total profit reported was 1,026.60 million yuan, with a net profit attributable to shareholders of 822.12 million yuan, and a net profit after deducting non-recurring gains and losses of 774.45 million yuan [4]. Reasons for Profit Decline - The significant decrease in profit is primarily due to the need for the company's subsidiaries to pay back taxes and penalties totaling approximately 100 million yuan, including 80 million yuan for income tax and 20 million yuan for value-added tax and penalties [5]. Earnings Forecast and Communication - The company has expressed sincere apologies to investors for the discrepancies in the earnings forecast and is committed to improving the accuracy of future earnings predictions [7]. - The revised earnings forecast data is preliminary and subject to final confirmation by the auditing firm in the annual report [6]. - The company has not identified any other significant uncertainties that could affect the accuracy of this earnings forecast [6]. - The board of directors will enhance communication with the annual audit accountants to ensure the scientific and accurate nature of earnings forecasts [8].

证券代码：600129 证券简称：太极集团 公告编号：2025-017 重庆太极实业（集团）股份有限公司 关于子公司补缴税款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 2025 年 3 月 26 日，重庆太极实业（集团）股份有限公司（以下 简称：公司）控股子公司西南药业股份有限公司（以下简称：西南药 业）和公司全资子公司重庆中药材有限公司（以下简称：中药材公司） 根据当地税务检查和企业自查情况，西南药业、中药材公司需补缴税 款及滞纳金共计约 10,000 万元。其中：西南药业需补缴税款约 8,000 万元；中药材公司需补缴税款及滞纳金约 2,000 万元。现将有关情况 公告如下： 一、基本情况 1 公司管理层对上述事项高度重视，将持续深化对下属子公司监督 管理，加强税务等专业知识培训和学习，强化责任意识，切实维护公 司及股东利益。敬请广大投资者注意投资风险。 特此公告。 重庆太极实业（集团）股份有限公司 2025 年 3 月 27 日 2 根据国家税务总局重庆市税务局第三稽查局对西南药业检查情 况，以及中药材公司 ...

| 1、出席会议的股东和代理人人数 | 853 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 192,483,110 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 34.5638 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由董事会召集，董事长俞敏先生主持，本次会议的召集、召开及表 决方式均符合《公司法》及《公司章程》的有关规定。 1 证券代码：600129 证券简称：太极集团 公告编号：2025-016 重庆太极实业（集团）股份有限公司 2025 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 3 月 20 日 (二) 股东大会召开的地点：重庆市渝北区恒山东路 18 号公司 1201 楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及 ...